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Human papillomaviruses (HPVs) are the causative agents of cervical and other cancers. The oncoprotein
E7 activates the cell cycle and makes possible replication of the viral genome in differentiating epithelia.
The HPV16 late promoter is activated upon cellular differentiation and regulates late gene expression. We
investigated the effect of E7 on the late promoter and found that E7 was able to activate the promoter. In
contrast, the other known viral transcriptional regulator, E2, had no effect on the late promoter. Promoter
activation by E7 occurred despite inhibition of promoter activity by factors involved in the cell cycle, such
as cyclin dependent kinases and E2F transcription factors, and by the ability of E7 to disrupt several
aspects of cellular differentiation. These results suggest a new role for E7 in the context of the viral life
cycle and shed light on the complex regulation of viral gene expression in infected, differentiating
epithelia.
& 2013 Elsevier Inc. All rights reserved.Introduction
Human papillomaviruses (HPVs) are small, non-enveloped DNA
viruses that persistently infect the keratinocytes of stratiﬁed
squamous epithelia (zur Hausen, 2009). Genital HPVs are the most
common sexually transmitted disease (STD) agents, and certain
“high risk” HPV types are necessary for the development of cervical
cancer, which is a leading cause of cancer mortality in women
worldwide (Parkin and Bray, 2006; Weinstock et al., 2004). In
normal stratiﬁed epithelia, the only actively dividing cells are the
basal cells located adjacent to the basement membrane. As basal
cells divide, one daughter detaches from the basement membrane
and begins to differentiate. Differentiating cells withdraw from the
cell cycle and undergo a complex, highly regulated series of
changes in gene expression (Simpson et al., 2011; Watt, 1998).
Ultimately the cells die and are shed into the environment. HPV
establishes infection in the long-lived cells of the basal layer,
where viral genomes are maintained at approximately 50–100
copies per cell and viral gene expression is low. As host cells move
from the basal layer and undergo differentiation, viral replicationll rights reserved.
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State University –Shreveport,and gene expression are activated in a tightly regulated and
stepwise manner resulting in the formation of virus particles in
the most superﬁcial layers and shedding into the environment
(Bodily and Laimins, 2011).
High risk HPV infections typically last 1–2 years (Moscicki et al.,
2006; Richardson et al., 2003; Woodman et al., 2001), but
persistence by HPV over longer periods facilitates the accumula-
tion of secondary cellular mutations and is thus the single most
important risk factor for the development of HPV-induced cancers
(Markowitz et al., 2007; Stanley, 2008; Woodman et al., 2001).
Each step of the HPV life cycle is designed to maximize the ability
of the virus to remain undetected in tissue for long periods (Bodily
and Laimins, 2011). Since the capsid proteins L1 and L2 are major
antigens, high level viral protein synthesis is restricted by a variety
of mechanisms to the highly differentiated layers where immune
surveillance is thought to be less stringent (Frazer, 2009). One of
these mechanisms is that the late promoter, which drives expres-
sion of these genes, depends on cellular differentiation for its
activity (Middleton et al., 2003; Peh et al., 2002; Ruesch and
Laimins, 1998). In addition to driving expression of the capsid
genes, the late promoter controls expression of viral regulatory
proteins (E1, E2, E1^E4, and E5) involved in ampliﬁcation of the
viral genome (Fehrmann et al., 2003; Hummel et al., 1992; Ozbun
and Meyers, 1997, 1998; Peh et al., 2004; Wilson et al., 2005). As a
result, viral copy number increases to several thousand copies per
cell in a differentiation-dependent manner (Bedell et al., 1991).
Fig. 1. HPV genes needed for late promoter activation. (a) The early region of the
HPV16 genome, with the locations of the early and late promoters, the long control
region (LCR), and the E1 splice donor. The region contained in the late promoter
luciferase reporter is indicated. (b) HFK cells, HFKs containing the episomal HPV16
genome, or HFKs expressing E6 or E7 from retroviral vectors were transfected with the
late promoter reporter and incubated for 24 h in monolayer or MC culture. Luciferase
values were normalized to Renilla luciferase internal controls and to the monolayer
value for each cell type. Values are the mean of 5-12 experiments. Bars represen-
t7one standard error of the mean.
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high level genome replication and capsid protein expression to the
proper place in the tissue. Some work has been done to map which
differentiation-speciﬁc cellular factors contribute to promoter
activity (Bodily et al., 2006; Bodily and Meyers, 2005;
Gunasekharan et al., 2012; Kukimoto and Kanda, 2001; Kukimoto
et al., 2006; Spink and Laimins, 2005), but details of its regulation
remain elusive.
Differentiation-dependent compartmentalization of HPV gene
expression is an important persistence strategy, but it creates a
difﬁculty for the virus. Because the virus does not encode its own
DNA replication factors, cellular DNA synthesis proteins are needed
for productive viral replication. However, keratinocytes withdraw
from the cell cycle upon differentiation and these cellular factors
become unavailable to the virus (Watt, 1998). To circumvent this
problem, the HPV forces differentiating cells to reenter the cell cycle,
thus enabling viral DNA replication in cells that would otherwise be
non-permissive (Munger et al., 2004). The viral protein primarily
responsible for driving the cell cycle and maintaining replication
competence in differentiating cells is E7. The major known activity of
E7 is to bind to and inactivate members of the pRb family, resulting
in the release of E2F transcription factors to promote expression of
genes that produce an S phase-like environment. Degradation of the
pocket protein p130 by E7 is thought to delay differentiation,
allowing the virus a chance to replicate its genome (Klingelhutz
and Roman, 2012). Additional activities of E7 are also reported,
including regulation of transcription through binding to a wide
variety of transcriptional regulatory factors, primarily through the C
terminus. The roles of these interactions in the viral life cycle or in
cancer development are unclear.
One consequence of viral oncogene expression is the creation
of an unusual cellular environment in which cell cycling and
differentiation, which are normally mutually exclusive processes,
can occur simultaneously, albeit in modiﬁed form (Davy et al.,
2005; McCance et al., 1988). How these two important processes
interrelate in HPV-infected cells is not entirely clear, but late
events in the viral life cycle, including transcription from the late
promoter, have undoubtedly evolved to occur under these speciﬁc
conditions. Because forced cell cycling is also central to the
tendency of high risk HPV-induced lesions to progress to malig-
nancy, understanding the interaction between differentiation and
the cell cycle during HPV infections will illuminate the conditions
under which HPV-induced cancers arise.
This study grew out of previous work in which we performed
extensive mutagenesis of the E7 open reading frame (ORF) in the
context of the complete viral genome in order to better under-
stand the functions of E7 in the viral life cycle (Bodily et al., 2011a).
Because the late promoter is imbedded within the E7 ORF, there
was a chance that our mutations would impact cis promoter
elements, which turned out to be the case for some mutants.
However, it was also possible that mutation of E7 could somehow
affect promoter activity through an effect on E7 protein in trans.
Because of the antagonistic relationship between cell cycling,
which is induced by E7, and differentiation, which is required for
promoter activity, we expected that any effect of E7 protein
expression on promoter activity was likely to be negative. Instead,
we uncovered a novel and unexpected ability of E7 to activate the
HPV16 late promoter. Activation by E7 was independent of
transcriptional regulation by E2, which we found does not regulate
the HPV16 late promoter. Late promoter activation was mapped to
motifs in E7 that regulate the cell cycle. Despite the ability of E7 to
promote cell cycle progression, we found that factors that promote
cell cycle progression markedly antagonized promoter activation.
These data describe a new function for E7 and highlight the
tension between differentiation-dependence and promotion of
cell cycling in the HPV life cycle.Results
HPV contributes to activation of its own late promoter
To test whether viral oncogenes including E7 would have an
effect on late promoter activation, we cloned a portion of the HPV
genome extending from just downstream of the early promoter to
the beginning of the E1 ORF, into a luciferase reporter plasmid
(Fig. 1a). The reporter was transfected into human foreskin kerati-
nocytes (HFKs), which do not contain any HPV gene products, or
into HFKs expressing the viral oncogenes from the complete HPV16
genome. Following transfection, the cells were divided and cultured
as monolayers (which models the undifferentiated condition) or
suspended in semisolid medium containing 1.6% methylcellulose
(MC, which induces differentiation of the keratinocytes). After 24 h
of culture, lysates were harvested and assayed for luciferase
reporter activity. The activity of this reporter was increased upon
differentiation in cells containing HPV16 genomes, as expected
(Fig. 1b). However, no increased activity was seen upon differentia-
tion of uninfected HFKs. Transfection of HFKs and HPV16 cells
had no effect on their ability to differentiate in MC, as measured by
increased levels of the differentiation marker involucrin (not
shown). This result indicated that some HPV gene product is
required for late promoter activation. It also indicated that the late
promoter responds to signals in addition to differentiation alone.
E7 increases late promoter activation in differentiated keratinocytes
We next sought to identify the viral gene product responsible
for activation of the late promoter. We transfected the late
promoter reporter into HFKs that stably express either HPV16 E6
or E7 from retroviral vectors. Transfected cells were divided and
grown in monolayer or MC culture as before, and luciferase
activity was measured. As shown in Fig. 1b, E6 and E7 were each
sufﬁcient in the absence of other viral factors to support late
promoter activation to some degree upon differentiation, but E7
was much more efﬁcient than E6. Thus we focused primarily on E7
in subsequent studies.
We were surprised to ﬁnd that E7 could support differentiation-
dependent late transcription because E7 is reported to interfere with
certain aspects of differentiation (McCance et al., 1988). To clarify this
J.M. Bodily et al. / Virology 443 (2013) 11–19 13issue, we examined the effect of the complete HPV16 genome and of
E7 alone on induction of transcripts for several well-characterized
cellular differentiation markers upon culture in MC using RT-qPCR.
We found that the complete HPV16 genome dramatically reduced
transcript levels for each of the cellular transcripts tested (Fig. 2).
Inhibition was seen both in basal conditions in monolayer, and upon
induction of differentiation in MC. These data demonstrate that the
late promoter is activated in a cellular differentiation environment
that differs signiﬁcantly from that seen in an uninfected keratinocyte
undergoing differentiation, suggesting that the promoter has evolved
to respond not to the normal keratinocyte differentiation signals but
to the modiﬁed differentiation program present in a cell containing
viral oncogenes. In keratinocytes immortalized by E7 alone, activa-
tion of differentiation markers was more variable and seemed to fall
into two groups: keratin 1 (K1) and K10 were both efﬁciently
inhibited by E7, while involucrin and transglutaminase 1 transcripts
were not. The effect of E7 on the late differentiation markers loricrin
and ﬁlaggrin was inconsistent, although both markers were consis-
tently inhibited by the complete HPV16 genome (not shown).
Transfected E7 can activate the late promoter
Because E7 is required for immortalization of primary keratino-
cytes, mutating E7 or manipulating expression levels under stable
expression conditions, such as from the complete viral genome, is
problematic. Although overexpression may generate non-
physiological E7 levels, transient transfection provides ﬂexibility
for further molecular analyses. Thus we wished to know whether
E7 expressed from a plasmid vector in a transient transfection
would be able to activate the late promoter. For these experiments
we transfected the late promoter reporter, with or without an
expression vector for E7, into HFK cells or HFKs maintaining
episomal HPV16. We then assayed for luciferase activity after 24 h
of culture in monolayer or MC. E7 was able to activate the late
promoter in HFKs under transient conditions (po0.01, Fig. 3a).
Activation by E7 was seen in both monolayer and MC. We found
that E7 was also able to activate the promoter in HPV-containing
cells, both in monolayer and in MC (po0.01). This effect was found
to be responsive to the amount of E7 transfected (not shown). E7
was also able to increase late promoter activity when transfected
into U2OS cells, which are derived from an osteosarcoma (not
shown), indicating that the mechanism of E7-mediated promoterFig. 2. HPV16 reduces expression of cellular differentiation marker transcripts. The indic
were isolated and subjected to RT-qPCR using primers speciﬁc for involucrin (INV), tran
change in gene expression normalized to Cyclophilin A as an internal control and relativ
cells from at least two genetic backgrounds each with 6–9 individual PCR reactions. Baactivation is not keratinocyte speciﬁc. By contrast, when E6 was
transiently cotransfected, signiﬁcant activation of the promoter in
MC was not seen (p40.05); modest augmentation of E7's activity
was seen when it was cotransfected with E6 (po0.02; Fig. 3b). To
determine whether E7-mediated activation was speciﬁc to the
HPV16 late promoter or to 16E7, we transfected the HPV31 late
promoter (Spink and Laimins, 2005) with expression vectors for
31E7 or 16E7 into HPV16-containing HFKs. Enhanced levels of
promoter activity were seen with both 16E7 and 31E7 (po0.05;
Fig. 3c). Because the activating effect of E7 was seen in HPV-
containing cells, and these cells grow more easily and consistently
than HFK cells, we performed most of our subsequent experiments
in cells containing episomal HPV16.E7 and E2 have independent transcriptional functions
Our results suggested that E7 could act as a regulator of viral
transcription. To understand the mechanism, we ﬁrst considered a
role for the HPV E2 protein, which is the best characterized
regulator of HPV transcription. E2 is thought to perform its
transcriptional regulatory activities by binding to speciﬁc sites in
the viral regulatory region and, among other proposed mechan-
isms, interacting with the cellular chromatin binding protein Brd4,
which serves to recruit the elongation factor P-TEFb (Schweiger
et al., 2007; Wu and Chiang, 2007; Yan et al., 2010). Recent data
have shown that E7 and E2 are able to interact physically, and that
E2 can interfere with E7's transforming activities (Gammoh et al.,
2006,, 2009). The ability of E2 to regulate the late promoter has not
been tested, and its transcriptional activity in differentiated con-
ditions is also not well understood. Having found that E7 could
activate the late promoter, we were curious whether E7 might act
by reversing an inhibitory effect of E2. To test this possibility, we
measured late promoter reporter activity with or without cotrans-
fection of E7 and E2 expression vectors. There was no effect of E2
alone on late promoter reporter activity or the activity of E7 in MC
(p40.1, Fig. 4a). A modest increase in reporter activity by E2/E7 as
compared to E7 alone was seen in monolayer (po0.05). Cotrans-
fection of the viral E8^E2C repressor protein had no effect (not
shown). Because E2 had no real effect on late promoter activity, we
conclude that E7's ability to activate the late promoter is unlikely
to be due to alterations in the activity of E2.ated cell types were cultured for 24 h in monolayer or suspended in MC. Total RNAs
sglutaminase 1 (TGM1), Keratin 1 (K1) or Keratin 10 (K10). Values represent a fold
e to HFK monolayer samples. Values represent the means of 2–3 experiments using
rs represent71 standard error of the mean.
Fig. 3. E7 alone can activate the late promoter. Uninfected HFK cells (a) or HPV16-
containing keratinocytes (a–c) were cotransfected with luciferase reporters for the
HPV16 (a, b) or HPV31 (c) late promoters along with the indicated E7 expression
vectors. Following culture in monolayer or MC for 24 h, luciferase activities were
measured and normalized as described in Fig. 1. V, pcDNA empty vector. Values
represent the means of 3–17 independent experiments and bars represent 71
standard error of the mean.
Fig. 4. Role of E2 and E7 in late and early promoter activity. HPV16-containing
keratinocytes were cotransfected with luciferase reporters for the late promoter
(a) or the LCR-driven early promoter (b) and expression vectors for E7 and/or E2.
Following culture in monolayer or MC for 24 h, luciferase activities were measured
and normalized as described in Fig. 1. V, pcDNA empty vector. Values represent the
means of ﬁve independent experiments and bars represent 71 standard error of
the mean.
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speciﬁc to the late promoter. E2 is well known to inhibit the
activity of the viral early promoter, which is contained in the long
control region (LCR) in the viral genome (Thierry, 2009). Because
E2 expression is driven from the early promoter, repression by E2
represents an autoregulatory loop controlling viral early promoter
activity. E7 expression is also driven from the early promoter, so
we tested whether E7 could likewise regulate the early promoter
or modify early promoter inhibition by E2. Using a luciferase
reporter containing the HPV16 LCR, we found that E2 was able to
inhibit transcription from the LCR in monolayer culture as
expected (po0.01; Fig. 4b). However, inhibition by E2 largely
disappeared in cells differentiated in MC (p40.2). E7 was able to
increase activity of the LCR reporter, but only by about 2 fold
(po0.05), which is much less than the effect of E7 on the late
promoter. When both viral proteins were expressed together, acombination effect was seen, in which E2 was able to reduce
activity relative to E7 alone and E7 was able to increase the activity
relative to E2 alone (po0.01). Again, E2 had no effect on LCR-
driven reporter activity in MC (p40.4). Together, these data
suggest that the activity of E2 is primarily directed toward the
early promoter, whereas E7 most clearly affects late promoter
activity. They also suggest that modifying the activity of E2 cannot
account for the ability of E7 to activate late transcription and that
E2 does not act as an inhibitor of the early promoter under
differentiating conditions.
pRb binding and C terminal domains of E7 contribute to late
promoter activation
Our previous studies found that HPV16 genomes harboring
certain E7 mutants. (Fig. 5a) were less efﬁcient at activating the
late promoter and producing infectious particles than wild type
(Bodily et al., 2011a). These included L67R, which disrupts the C
terminal zinc-ﬁnger like domain and cannot bind histone deace-
tylases (Brehm et al., 1999), and CVQ-AAA, which has been shown
to be defective in preventing p21CIP1-mediated growth arrest by
E7 (Helt et al., 2002) and to have reduced binding to E2F-6
(McLaughlin-Drubin et al., 2008). To conﬁrm that these E7
mutants have a defect speciﬁcally in supporting late promoter
activation, we cotransfected expression vectors for these mutants
along with the late promoter reporter into HPV-containing kera-
tinocytes and measured luciferase activity after culture in mono-
layer and MC. Neither L67R nor CVQ was able to activate the
promoter as well as wild-type, consistent with our data from the
complete genome (po0.05). The LYCYE deletion mutant of E7 is
unable to bind pRb, and because genomes containing this mutant
are not maintained episomally, we were not previously able to
discover an effect of this mutant on late viral activities (Bodily
et al., 2011a). In transient transfections, however, we found that
LYCYE was reduced in its ability to increase promoter activation
Fig. 5. Mutations of E7 in late promoter activation. (a) A diagram of important
domains in the E7 protein, with the locations of mutations used in this study.
(b) HPV16-containing keratinocytes were cotransfected with luciferase reporters
for the late promoter and expression vectors for E7 mutants. Following culture in
monolayer or MC for 24 h, luciferase activities were measured and normalized as
described in Fig. 1. V, pcDNA empty vector; CVQ, CVQ68-70AAA. Values represent
the means of 9-14 independent experiments and bars represent 71 standard error
of the mean. Samples marked with (*) were signiﬁcantly different from wild-type
E7 in the corresponding culture condition (monolayer or MC, po0.05). (c) To
determine expression levels of mutant E7s, U2OS cells were transfected with the
indicated expression vectors for E7 and subjected to Western blotting analysis.
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pRb but not degrade it, could activate the late promoter as well as
wild type (p40.2), suggesting that pRb binding may be important
for promoter activation but that pRb degradation is not. This raises
the possibility that the E7s of low-risk HPV types could also
stimulate their respective late promoters, although further experi-
ments are needed to test it. Mutants in the casein kinase II
phosphorylation site were indistinguishable from wild type (not
shown), consistent with the observation that these mutations in
the context of the complete genome have no defect in promoter
activation. We conﬁrmed by Western blotting that our mutants
were all expressed at comparable levels (Fig. 5c). Thus, the effects
of the different mutations were consistent with our previous
results in the context of the complete HPV16 genome (Bodily
et al., 2011a). We conclude that the C terminus, which is impli-
cated in p21CIP1, HDAC, and E2F-6 interactions, and also the pRb
binding site, have roles in E7-mediated late promoter activation.
In addition to the concern that transient transfection may result in
non-physiological levels of E7, the DNA sequence of the late promoter
and the E7 ORF overlap, so it was possible that the DNA in the E7
expression plasmid could bind to and titrate away a DNA-binding
repressor protein from the reporter, resulting in increased promoter
activity. Consistent with this latter possibility, we found that a non-
translatable mutant of E7 (Stop) could increase reporter activity in our
transient transfections, indicating that some promoter activation in
transient transfections could be due to the DNA present in the E7
expression plasmid rather than the E7 protein alone (Fig. 5b). This
could explainwhy none of the other mutations was able to completely
eliminate promoter activation by E7, and may be consistent with amodest observed effect of DNA copy number on promoter activation in
the context of the complete viral genome (Spink and Laimins, 2005).
However, the Stop mutant was less effective than wild type in
increasing reporter activity (po0.05), indicating that E7 protein
expression is needed for full promoter activation by E7 cotransfection
in our experiments.
Mitotic CDKs are not necessary for late promoter activation
Although complicated by background levels of activation, our
mutational analysis implicated the pRb family and perhaps p21CIP1
or E2F-6 as possible targets of E7 involved in late promoter activa-
tion. These factors function primarily as regulators of cell cycle
progression, suggesting that cell cycling may contribute to promoter
activity. In many cell contexts, differentiation and cell cycle progres-
sion are mutually exclusive. Inhibition of the cell cycle is well
established to promote differentiation of keratinocytes (Freije et al.,
2012; Gandarillas et al., 2000), which would be expected to increase
late promoter activity. In the context of HPV infection, cell cycling
coexists with differentiation, although both are modiﬁed. As we
show above, and as others have also shown (McCance et al., 1988),
HPV can delay or disrupt both the expression of differentiation
markers and tissue morphology. Additionally, HPV-infected cells are
known to arrest at G2 and thus may not be cycling in a conventional
sense (Davy et al., 2005). It was therefore of interest to understand
how an oncoprotein known to activate the cell cycle could also
activate a differentiation-dependent promoter. We hypothesized that
the late promoter has evolved to respond to both differentiation and
the cell cycle, and that cell cycle activation by E7 is responsible for its
activating effect. If the cell cycle were somehow necessary for
promoter activation, inhibition of the cell cycle should lead to a
reduction in promoter activity. Four CDKs are primarily responsible
for cell cycle progression: CDK1, 2, 4, and 6. Cotransfection of
p21CIP1, a cellular inhibitor of CDK2, CDK4, and 6, had no effect on
either basal or E7-induced promoter activity (not shown). Treatment
with a chemical inhibitor of CDK4/6 had only a slight effect on the
activation of the endogenous late promoter in cells containing HPV16
episomes (Fig. 6a).
We next studied the contribution of CDK1 and CDK2 by
cotransfecting dominant negative (DN) mutants. We found that
both DN CDKs could increase luciferase activity in monolayer and
in MC (po0.01; Fig. 6b), consistent with the ability of cell cycle
inhibition to promote differentiation (Freije et al., 2012;
Gandarillas et al., 2000). This effect also suggests that endogenous
CDK1 and CDK2 antagonize rather than activate the late promoter.
We found that E7 was able to activate the promoter to high levels
even in the presence of the DN-CDKs (po0.05), suggesting that
neither CDK1 nor CDK2 activity is necessary for the ability of E7 to
increase promoter activity. Together, these results suggest that cell
cycle progression, and mitotic CDK activity in particular, is not
necessary for HPV16 late promoter activation by E7, but that the
endogenous CDK1 and CDK2 antagonize promoter activity.
Activating E2Fs antagonize late promoter activation
To further understand the relationship between cell cycling and
promoter activation, we returned to our observation that the pRb
binding domain of E7 was necessary for promoter activation by E7.
Given that the pRb binding domain of E7 was important for
promoter activation, but pRb degradation was not, it was possible
that E7's ability to disrupt E2F/pRb complexes may be important
for promoter activation, since this does not require pRb degrada-
tion (Helt and Galloway, 2001). We considered the possibility that
if E2F transcription factors were to activate the promoter, E7 could
increase promoter activity by inactivating pRb and liberating E2Fs.
To test the effect of E2F transcription factors, we cotransfected
Fig. 6. Role of CDKs in regulating promoter activity. (a) Keratinocytes maintaining
episomal HPV16 were treated or untreated with a CDK4/6 inhibitor and total RNAs
were subjected to Northern analysis using the HPV16 genome as a probe.
(b) HPV16-containing keratinocytes were cotransfected with luciferase reporters
for the late promoter and expression vectors for E7, DN-CDK1, or DN-CDK2.
Following culture in monolayer or MC for 24 h, luciferase activities were measured
and normalized as described in Fig. 1. V, pcDNA empty vector; pGL, empty
luciferase reporter vector. Values represent the means of 5–9 independent experi-
ments and bars represent 71 standard error of the mean.
Fig. 7. Role of E2Fs in regulating promoter activity. HPV16-containing keratino-
cytes were cotransfected with luciferase reporters for the late promoter and
expression vectors for E7 or the indicated E2F expression vectors. Following culture
in monolayer or MC for 24 h, luciferase activities were measured and normalized as
described in Fig. 1. V, pcDNA empty vector; pGL, empty luciferase reporter vector.
Values represent the means of 4–8 independent experiments and bars represent
71 standard error of the mean.
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only failed to activate but completely eliminated E7-mediated
promoter activation (po0.02; Fig. 7a). The levels of E2F expression
in this experiment were not sufﬁcient to cause signiﬁcant cell
death (not shown). A mutant of E2F-1 that fails to bind pRb, Y411C,
also inhibited E7-mediated activation (Fig. 7b), indicating that the
ability of E2F1 to inhibit E7-mediated promoter activation is not
dependent on its ability to bind to pRb. We conclude that the S
phase-promoting E2F family members can inhibit late promoter
activation by E7 and thus activation of E2F transcription factors by
E7 is not likely to be responsible for promoter activation.
A subset of E2Fs is capable of repressing rather than activating
transcription and can thus interfere with cell cycle progression
(Frolov and Dyson, 2004). E7 binding to one of these, E2F-6,
counteracts its repressing activity (McLaughlin-Drubin et al.,
2008). Because the CVQ mutant, which has reduced binding to
E2F-6, is also defective for promoter activation, we were curious
whether E2F-6 would have any effect on the late promoter. We
found that E2F-6 did not prevent promoter activation as E2F-1 did,
but that it enhanced activation by E7 by a modest but reproducible
30–40% (po0.05; Fig. 7c), consistent with the ability of E2F-6 to
inhibit cell cycle progression.
Instead of the cell cycle being necessary for promoter activity as
we originally hypothesized, our data so far suggested that the cell
cycle may in fact antagonize the late promoter. If so, we predicted
that the inhibitory effect of E2Fs on E7-mediated promoter
activation would be reversed by a factor that blocks the cell cycle.
We tested this idea using DN-CDK1. As before, promoter activation
by E7 was reduced the in presence of additional E2F-1 (po0.01,
Fig. 8a). However, the effect of E2F-1 was reversed upon addition
of DN-CDK1, suggesting that the ability of E2F-1 to inhibit the
promoter was due to activation of the cell cycle, and thatinhibiting the cell cycle facilitated promoter activation by E7. Thus
the cell cycle antagonizes late promoter activation.Discussion
We have found that an HPV early gene product, E7, can activate
the viral late promoter. Late promoter activation represents a new
function for E7 in the context of the normal viral life cycle. The
concept of transcriptional cascades, in which late gene expression
depends on expression of early genes, is hardly a novel idea in
virology. For example, activation of downstream promoters to
express genes involved in genome replication is a primary function
of the adenovirus E1A protein (Berk, 2005). Given that E7 shares
signiﬁcant functional and sequence similarity with E1A, and that
the genes immediately downstream of the HPV16 late promoter
are involved in viral genome replication, perhaps it should not be
surprising that E7 would similarly serve to activate the HPV late
promoter. The HPV16 late promoter has long been known to
respond to differentiation (Grassmann et al., 1996) and studies of
the promoter have focused on that aspect of its regulation. Thus it
Fig. 8. Promoter inhibition by E2F-1 is cell cycle dependent. HPV16-containing keratinocytes were cotransfected with luciferase reporters for the late promoter and
expression vectors for E7 or the indicated E2F expression vectors. Following culture in monolayer or MC for 24 h, luciferase activities were measured and normalized as
described in Fig. 1. V, pcDNA empty vector; pGL, empty luciferase reporter vector. Values represent the means of 4-8 independent experiments and bars represent 71
standard error of the mean. *po0.01; n.s., not signiﬁcant.
J.M. Bodily et al. / Virology 443 (2013) 11–19 17has generally been assumed that the role of the virus in activation
of the promoter is largely passive: that the virus lies quiescent
until the cell provides the signals needed to turn on transcriptional
activity. The ability of E7 to activate the promoter while at the
same time inhibiting some aspects of differentiation suggests that
the virus plays an active role in regulating its own late genes and
that late promoter regulation is more complex and multifaceted
than has been previously appreciated.
Given what we knew at the beginning of these studies about
the cell cycle and promoter activation, our hypothesis was that E7
would inhibit the promoter by activating cell cycle progression.
Indeed, the data presented above support our assumption that cell
cycle progression would antagonize promoter activity. However,
our hypothesis was incorrect. We found instead that E7 has some
other activity, apparently distinct from its ability to activate the
cell cycle, which serves to promote late transcription. It was
possible that some combination of cell cycling and differentiation
would provide the signals needed for proper promoter regulation.
However, we were unable to ﬁnd evidence that the cell cycle
contributes positively to late promoter activity.
The cells in which the late promoter is activated are highly
unusual in their combination of differentiation and cell cycling.
Aside from lymphocytes, which proliferate as they differentiate, it
is unusual to ﬁnd cells in which both of these processes occur
simultaneously. HPV-infected keratinocytes are active in the cell
cycle through the functions of E6 and E7, but cell cycling is
modiﬁed by the induction of G2 arrest (Davy et al., 2005). Infected
cells also show many aspects of differentiation, as indicated by the
upregulation of differentiation-dependent cellular markers and
characteristic changes in cellular morphology. However, differen-
tiation of infected cells is modiﬁed by the presence of viral
oncogenes, and it is likely that HPV has evolved to inhibit those
aspects of differentiation that are detrimental to its multiplication
while retaining those that are helpful. Previous work has shown
that protein products of the late promoter are high in cells
expressing TGM and involucrin but not in cells expressing K10
(Ruesch et al., 1998), indicating that promoter activation correlates
with some differentiation-related events but not others. Clearly
those differentiation-related pathways needed for late promoter
activation must be preserved in the presence of the viral onco-
genes, but how HPV selects which pathways to preserve and
which to inhibit will require further molecular studies.
Although withdrawal from the cell cycle is considered to be a
hallmark of keratinocyte differentiation, and inhibition of the cell
cycle can promote differentiation (Fig. 6 and Freije et al., 2012;
Gandarillas et al., 2000), the relationship between cell cycling and
differentiation in keratinocytes is not entirely clear. Some reportsindicate that even uninfected HFKs are capable of DNA replication
without cell division as they differentiate (Freije et al., 2012;
Gandarillas et al., 2000), and that a signiﬁcant fraction of differ-
entiated keratinocytes from various body sites in humans are in
fact polyploid (Zanet et al., 2010). This suggests that endoredupli-
cation is a common phenomenon in differentiating keratinocytes
and that the DNA synthesis machinery may not be entirely
quiescent in these cells. The dual ability of E7 to promote both
the cell cycle and transcription from a differentiation-dependent
promoter may be analogous to the oncogene c-Myc, which can
induce cell cycling in a wide variety of cells, but is needed for both
cell cycling and differentiation in keratinocytes, depending on the
differentiation stage (Gandarillas et al., 2000). Although inhibitors
of c-Myc had no effect on late promoter activity in our HPV-
containing keratinocytes (not shown), it is possible that more
detailed studies of how E7 manipulates both cell cycling and
differentiation-dependent gene expression may shed light on
differentiation in the absence of infection.
E7 protein levels decline upon differentiation (data not shown
and Isaacson Wechsler et al., 2012). However, studies of natural
lesions have shown that markers of E7 are found in the population
of cells that initiates expression of E1^E4 (which is a major
product of the late promoter; Isaacson Wechsler et al., 2012),
indicating that E7 is positioned to activate the promoter in vivo,
consistent with our results. We extensively used transient over-
expression in the experiments reported here, which carries the
risk of non-physiological effects due to high protein levels. Thus it
will be important to strengthen the conclusions of this study with
additional work under more stable expression conditions. In that
regard, our previous work showed that CVQ mutant HPV16
genomes stably maintained in keratinocytes were less efﬁcient at
activating the late promoter than wild type, and that L67R mutant
genomes were moderately capable of supporting promoter activa-
tion but defective for the production of infectious virions (Bodily
et al., 2011a). Those results support our present study ﬁnding that
the CVQ and L67R mutants of E7 were both deﬁcient in promoter
activation, which could account in part for their late phenotypes in
the context of the complete genome. The phenotypes of these
mutants are also consistent with previous work indicating that the
C terminus of E7 is responsible for many of its transcriptional
activities in other promoter contexts (Avvakumov et al., 2003;
Brehm et al., 1999; Longworth et al., 2005; McLaughlin-Drubin
et al., 2008; Rawls et al., 1990).
It is a conundrum that E7, which activates the cell cycle, should
also activate the late promoter when the cell cycle antagonizes
promoter activity. Clearly some additional E7 activity or mechan-
ism must be involved. Although we have not yet identiﬁed the
Table 1
PCR primers used in this study.
Primer name Sequence
E2F1 Y411C 5′ ggccctcgactGccacttcggcctcgagga
E2F1 Y411C 3′ tcctcgaggccgaagtggCagtcgagggcc
qCyc 5′ cttgggccgcgtctcc
qCyc 3′ gcaggaacccttataaccaaatcc
INV 5′ ctctgcctcagccttactgtga
INV 3′ gctcctgatgggtattgactgg
TGM1 5′ gctggagatggcaccatcc
TGM1 3′ agctcgtcgtactcatactcgtctg
K1 5′ caagtcactcaacaaccaatttgC
K1 3′ ggtatctacctgctgcagcagc
K10 5′ agcctcgtgactacagcaaatactac
K10 3′ ctacctcattctcatacttcagcctg
Fig. 9. Model. Transcription initiation from the late promoter is increased in
response to cellular differentiation signals through the activity of differentiation-
speciﬁc transcription factors (TF-X) such as C/EBPβ (Bodily et al., 2006; Bodily and
Meyers, 2005; Gunasekharan et al., 2012; Kukimoto and Kanda, 2001; Kukimoto
et al., 2006; Spink and Laimins, 2005). E7 promoter transcription through activa-
tion of a speciﬁc transcription factor or coregulator (TF-Y), or through effects on the
general transcription machinery.
J.M. Bodily et al. / Virology 443 (2013) 11–1918mechanism for E7-mediated promoter activation, we know several
things about it: (1) It operates in spite of antagonism of the late
promoter by the cell cycle, suggesting that it is a function of E7
distinct from its ability to induce unscheduled S phase. (2) It
depends on sequences in both the CR2 domain and C terminus of
E7. (3) It can be completely blocked by E2F-1, -2 or -3 coexpression
in a cell cycle dependent manner, and inhibition by E2F1 does not
depend on pRb binding to E2F1. Our working model is found in
Fig. 9, in which cell cycle activation by E7 is offset by a second
activity which helps to activate the promoter. Whether this second
activity of E7 is mediated through effects on a speciﬁc transcrip-
tion factor, transcriptional coactivators, transcriptional elongation,
or some other transcriptional process remains to be determined.Materials and methods
Cell culture
Human foreskin keratinocytes (HFKs) were isolated from neo-
natal foreskins by enzymatic disaggregation with trypsin (Wilson
and Laimins, 2005). Cell lines immortalized by episomal HPV16
genomes or by expressing HPV oncogenes from retroviral vectors
were derived by transfection or infection of HFKs, followed by
selection and maintenance in E medium with 5% fetal bovine
serum and ﬁbroblast feeders as described previously (Bodily et al.,
2011a). Differentiation was induced by trypsinizing the cells and
suspending them in E medium containing 1.6% methylcellulose
(MC; Wilson and Laimins, 2005). U2OS cells were cultivated in
DMEM containing 10% bovine growth serum.
Plasmids and drugs
The late promoter luciferase reporter, expression vectors for E6
and E7, and mutants of E7 were described previously (Bodily et al.,2011a,, 2011b). Expression vectors were gifts from Laimonis
Laimins (pCMV-E2F1, –E2F2, –E2F3) and Bayar Thimmapaya
(pcDNA ﬂag-pRb) of Northwestern University School of Medicine;
Christine Suetterlin (pcEGFP CDK1-DN, CDK2-DN) of the Univer-
sity of California, Irvine; and Andrew Wells (pMINR1-E2F6) of the
University of Pennsylvania. CDK4/6 inhibitor was from EMD
Millipore (cat. # 219492). The Y411C mutation of E1F1 was created
using the primers in Table 1 to mutagenize pCMV-E2F1 using the
QuickChange II Site Directed Mutagenesis kit (Agilent).
Transfection and reporter assays
Transient transfections were performed using polyethylenei-
mine (PEI; Polysciences) as described (Bodily et al., 2011b).
Keratinocytes were transfected with reporter plasmids overnight
using PEI. The next day, cultures were divided and half of the cells
were plated in monolayer in 6 well plates, and half suspended in
5–10 ml 1.6% MC. Drugs were added to MC or monolayer media
prior to adding the cells. Following 24 h of incubation, lysates were
prepared and assayed for luciferase activity using the Dual-
Luciferases Reporter Assay System (Promega) according to man-
ufacturer's instructions, with Renilla luciferase as an internal
control. The total level of DNA in each transfection was kept
constant in each sample by addition of empty pcDNA vector DNA.
SDS-PAGE and Western blotting were performed as described
previously (Nakamura et al., 2009).
RNA extraction, Northern blotting, and qPCR
RNA-STAT 60 (TelTest, Inc) was used to isolate total RNAs.
Northern analysis was performed by subjecting total RNA to
agarose gel electrophoresis, transferring to a nylon membrane,
and using the complete HPV16 genome as a probe. Alternatively,
RNAs were DNAse treated and subjected to reverse transcription
using qScript™ cDNA SuperMix (Quanta). cDNA was subjected to
qPCR using the PerfeCTas SYBRs Green SuperMix ROX (Quanta)
on an Applied Biosystems StepOne Plus™ real time PCR machine.
Data are presented as a fold change in gene expression normalized
to Cyclophilin A as an internal control and normalized to the
reference sample. PCR primers used in this study are shown in
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